SCHEMBL2290718

SCHEMBL2290718

CC(C)(C)OC(=O)NC1Cn2c(=O)ccc3ccc(C#C[Si](C)(C)C)c1c32

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36
PDE10A Q9Y233 3/20 0.34
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
UCHL1 P09936 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRA4 P48169 1/20 0.32
GABRA6 Q16445 1/20 0.32
JAK3 P52333 2/20 0.32
BTK Q06187 1/20 0.32
SUV39H2 Q9H5I1 2/20 0.32
MAP4K4 O95819 2/20 0.31
CTSK P43235 2/20 0.31
JAK2 O60674 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722784 0.86 SUV39H2 (0.38) GAANFKB1NFKB2RELAJAK3
SCHEMBL1712785 0.86 GAA (0.36) GAAPDE10ANFKB1NFKB2RELA
SCHEMBL17311919 0.86 SUV39H2 (0.38) GAANFKB1NFKB2RELAJAK3
SCHEMBL1723447 0.81 GAA (0.39) GAAPDE10ANFKB1NFKB2RELA
SCHEMBL1723595 0.80 GAA (0.38) GAAPDE10ANFKB1NFKB2RELA
SCHEMBL1722713 0.80 GAA (0.38) GAAPDE10ANFKB1NFKB2RELA
SCHEMBL2286542 0.80 NFKB1 (0.40) GAAPDE10ANFKB1NFKB2RELA
SCHEMBL2287071 0.79 GAA (0.38) GAAPDE10ANFKB1NFKB2RELA
SCHEMBL1723562 0.75 GAA (0.39) GAAPDE10ANFKB1NFKB2RELA
SCHEMBL1723261 0.75 GAA (0.39) GAAPDE10ANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822114-B2 Tricyclic oxazolidinone antibiotic compounds IDORSIA PHARMACEUTICALS LTD (CH) 2017-11-21 US disclosed
US-20160237088-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS IDORSIA PHARMACEUTICALS LTD (CH) 2016-08-18 US disclosed
US-9346804-B2 Tricyclic oxazolidinone antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2016-05-24 US disclosed
EP-2344495-B1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2014-12-31 EP disclosed
US-20140142093-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2014-05-22 US disclosed
US-8618092-B2 Tricyclic oxazolidinone antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2013-12-31 US disclosed
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS HRH3, OXA1L, HRH1 GAA 4509/4885PDE10A 3935/4885NFKB1 1957/4885
US-20160237088-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS H1-3, HRH3, HRH4 GAA 4308/4885PDE10A 4072/4885NFKB1 2050/4885
US-20140142093-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS OXA1L, H1-3, NGLY1 GAA 4356/4885PDE10A 4084/4885NFKB1 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.